The paper reviews new peptide drugs being tested for advanced prostate cancer, like hormone‑blocking and hormone‑stimulating compounds, including some that act like growth‑hormone‑releasing hormone. While they can help the disease, they also cause side effects such as sexual problems, liver and kidney issues, bone loss, anemia and diarrhea. For people experimenting with health‑optimizing peptides, this study mainly warns that using similar compounds (e.g., sermorelin) could have serious risks if you have or are prone to prostate issues, and it doesn’t give any new dosing tricks for performance or longevity.

Increased understanding of prostate cancer biology has led to new treatment strategies and promising new agents for treating prostate cancer, in particular peptide-based agonists and antagonists. In this review article, new therapy modalities and potential approaches for the treatment of advanced prostate cancer are discussed, including agonists and antagonists of luteinizing hormone-releasing hormone, antagonists of bombesin/gastrin-releasing peptide, and growth hormone-releasing hormone and somatostatin analogues. Though the prognosis of patients with prostate cancer is much improved by some of these treatment approaches, including combination treatment methods, extensive side-effects are still reported. These include sexual dysfunction, functional lesions of the liver and renal system, osteoporosis, anaemia and diarrhoea. Future studies should focus on new treatment agents and treatment approaches that can eliminate side-effects and improve quality of life in patients with prostate cancer on the basis of potent treatment efficacy.